Added to YB: 2026-09-14
Pitch date: 2026-09-10
TYRA [neutral]
Tyra Biosciences, Inc.
Author Info
No bio for this author
Company Info
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
Market Cap
$1.3B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.08
P/E
-9.16
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conference coverage, Day 2 Section 1 - Tyra Biosciences, Inc.
TYRA (update): Tyra Biosciences’ oral selective FGFR3 inhibitor showed 100% overall response and 75% complete response at 60 mg in the single-marker-lesion group, the most relevant comparison with a competing oral study. The main thesis is adjuvant recurrence prevention after visible tumors are removed, not lesion ablation. The critical risk is whether short-term shrinkage translates into durable disease-free survival over one to two years in Phase 3.
Read full article (2 min)